tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Novo Nordisk Lowers 2025 Sales and Profit Outlook Amid Market Challenges

Story Highlights
  • Novo Nordisk revised its 2025 sales and profit outlook due to market challenges.
  • Despite strong first-half growth, expectations were lowered for Wegovy® and Ozempic® sales.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Novo Nordisk Lowers 2025 Sales and Profit Outlook Amid Market Challenges

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Novo Nordisk ( (NVO) ) has provided an update.

On July 29, 2025, Novo Nordisk announced a revised sales and operating profit outlook for 2025, reflecting a decrease in expected growth due to challenges in the US obesity and diabetes markets. Despite an 18% increase in sales and a 29% rise in operating profit in the first half of 2025, the company lowered its full-year expectations due to slower market expansion and competition, particularly affecting Wegovy® and Ozempic® sales. The company is actively pursuing strategies to counteract the impact of unlawful mass compounding and competition, while continuing to invest in commercial activities and direct-to-patient initiatives.

The most recent analyst rating on (NVO) stock is a Sell with a $81.50 price target. To see the full list of analyst forecasts on Novo Nordisk stock, see the NVO Stock Forecast page.

Spark’s Take on NVO Stock

According to Spark, TipRanks’ AI Analyst, NVO is a Outperform.

Novo Nordisk’s strong financial performance and positive earnings call highlights are the main contributors to its overall stock score. The company’s robust profitability, growth, and strategic initiatives support a favorable outlook. However, technical analysis indicates potential short-term challenges, and a reduced full-year guidance slightly tempers the overall score.

To see Spark’s full report on NVO stock, click here.

More about Novo Nordisk

Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. The company focuses on defeating serious chronic diseases, particularly in the field of diabetes, through scientific breakthroughs and expanding access to medicines. With a workforce of about 77,400 people in 80 countries, Novo Nordisk markets its products in around 170 countries. Its B shares are listed on Nasdaq Copenhagen and ADRs on the New York Stock Exchange.

Average Trading Volume: 9,486,346

Technical Sentiment Signal: Sell

Current Market Cap: $311.1B

See more insights into NVO stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1